AD/PD 2024
AD/PD-2024
International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders
05.05.- 09.05.2024
Lisbon, Portugal
AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference (kenes.com)
Meet Shimadzu at AP/PD 2024
For more than 30 years, scientists have been searching for biomarkers and blood tests that could efficiently predict the development of Alzheimer's and other neurodegenerative disorders. This is one of the great unmet needs in the society. If a test that requires just a few drops of blood and minimal intervention works, it could detect Alzheimer's disease early and help develop new treatments. Shimadzu has a long history in developing powerful analytical technologies and collaborates with researchers around the world to build a better future for people touched by dementia!
Join our expert to learn about blood biomarkers and analytical solutions based on Mass Spectrometry!
Visit our booth # 11
Plenary Talk
Title: MS TECHNOLOGIES FOR PLASMA BIOMARKER DEVELOPMENT
Speaker: Koichi TANAKA, Mass Spectrometry Research Laboratory, Shimadzu Corporation
Date: Tuesday, 5th March
Lecture Time: 17:35h - 18:05h
Room: Auditorium I
Click here to go to the abstract
Industry Symposium
Mass Spectrometry as a Tool for Early Diagnostics of Neurodegenerative Diseases
Date: Friday, 08.03.2024
Session Time: 18:40h - 19:40h
Session Type: SPONSORED SYMPOSIUM
Room: Auditorium I
In this session, the state-of-the-art in mass spectrometry and the developments for analyzing neurodegenerative diseases are presented. First, 2002 Nobel Prize winner Koichi TANAKA will highlight Shimadzu’s developments and innovations combining analytical and medical technologies. Second, Prof. Christophe HIRTZ will focus on the synergies of mass spectrometry and immunoassays and how to use these techniques to quantify synuclein in biological samples.
Title: Shimadzu, an innovative company making both analytical and medical instruments over a century.
Speaker: Koichi Tanaka - Mass Spectrometry Research Laboratory - Shimadzu Corporation - Japan
Title: Multiplex and targeted mass spectrometry and immunoassay for the quantification of the alpha, beta and gamma synuclein in biological samples in the context of neurodegenerative diseases
Speaker: Speaker: Prof. Christophe HIRTZ, Franc
Poster Presentation
CLINICAL PERFORMANCE EVALUATION OF PLASMA AMYLOID-ΒBIOMARKERS IN PREDICTING AMYLOID POSITIVITY IN COMMUNITY-BASED MILD COGNITIVE IMPAIRMENT COHORT
Takuya Ataka(1), Noriyuki Kimura(1), Naoki Kaneko(2), Tsukasa Takeuchi(2), Temmei Ito(3), Shinichi Iwamoto(2), Etsuro Matsubara(1)
(1) Department of Neurology, Oita University, Faculty of Medicine, Oita, Japan
(2) Shimadzu Corporation, Kyoto, Japan
(3) Eisai Co. Ltd., Tokyo, Japan
MALDI-MS METHOD DEVELOPMENT TO DETECT PHOSPHORYLATED TAU FRAGMENTS IN CEREBROSPINAL FLUID
Yusaku Hioki(1), Rie Yamamoto(1), Sadanori Sekiya(1), Shinichi Iwamoto(1), Koichi Tanaka(1)
(1) Shimadzu Corporation, Kyoto, Japan
ANALYSIS OF NEUROGRANIN RATIOS FOR AN EXPLORATION OF NEURODEGENERATION BIOMARKER
Naoki Kaneko(1), Ryota Takahashi(1), Takashi Kato(2), Yutaka Arahata(2), Sadanori Sekiya(1), Shinichi Iwamoto(1), Koichi Tanaka(1), Akinori Nakamura(2), BATON study group
(1) Shimadzu Corporation, Kyoto, Japan
(2) Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan
Product
Please contact us during the conference to get more information.
Service
Download our ebook "Early Detection Of ALZHEIMER’S BIOMARKERS Using Shimadzu’s Low-Cost, Blood-Based Amyloid Mass Spectrometry Service" now.
Publications
The Development of Plasma Amyloid β Assay and Its Significance in Alzheimer’s Disease
Naoki Kaneko, Ph.D.
The Development of Plasma Amyloid β Assay and Its Significance in Alzheimer’s Disease (shimadzu.com)
Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, Kyoto, Japan